ACUT
Price
$0.59
Change
-$0.01 (-1.67%)
Updated
Jun 5 closing price
Capitalization
9.98M
BLTE
Price
$59.67
Change
-$4.55 (-7.09%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
2.09B
61 days until earnings call
Interact to see
Advertisement

ACUT vs BLTE

Header iconACUT vs BLTE Comparison
Open Charts ACUT vs BLTEBanner chart's image
Accustem Sciences
Price$0.59
Change-$0.01 (-1.67%)
Volume$6.5K
Capitalization9.98M
Belite Bio
Price$59.67
Change-$4.55 (-7.09%)
Volume$2.61K
Capitalization2.09B
ACUT vs BLTE Comparison Chart
Loading...
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. BLTE commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and BLTE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ACUT: $0.62 vs. BLTE: $59.68)
Brand notoriety: ACUT and BLTE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 84% vs. BLTE: 264%
Market capitalization -- ACUT: $9.98M vs. BLTE: $2.09B
ACUT [@Biotechnology] is valued at $9.98M. BLTE’s [@Biotechnology] market capitalization is $2.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileBLTE’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • BLTE’s FA Score: 0 green, 5 red.
According to our system of comparison, ACUT is a better buy in the long-term than BLTE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLTE’s TA Score shows that 5 TA indicator(s) are bullish.

  • BLTE’s TA Score: 5 bullish, 5 bearish.

Price Growth

ACUT (@Biotechnology) experienced а +19.46% price change this week, while BLTE (@Biotechnology) price change was -8.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

BLTE is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BLTE($2.09B) has a higher market cap than ACUT($9.98M). ACUT YTD gains are higher at: 31.808 vs. BLTE (1.775). ACUT has higher annual earnings (EBITDA): -1.38M vs. BLTE (-35.42M). ACUT (0) and BLTE (0) have equivalent revenues.
ACUTBLTEACUT / BLTE
Capitalization9.98M2.09B0%
EBITDA-1.38M-35.42M4%
Gain YTD31.8081.7751,792%
P/E RatioN/AN/A-
Revenue00-
Total Cash37.1KN/A-
Total Debt57.6KN/A-
TECHNICAL ANALYSIS
Technical Analysis
BLTE
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 23 days ago
75%
Declines
ODDS (%)
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEURX29.45N/A
N/A
Franklin Mutual International Value Z
AGIFX18.53N/A
N/A
Alger Responsible Investing I
MSGAX11.74N/A
N/A
Meridian Small Cap Growth A
MFEHX185.08N/A
N/A
MFS Growth R3
AVASX22.25-0.04
-0.18%
American Beacon Large Cap Value Adv

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and KMSTF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and KMSTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
-1.58%
KMSTF - ACUT
28%
Poorly correlated
N/A
MOLN - ACUT
21%
Poorly correlated
-2.47%
PHGE - ACUT
20%
Poorly correlated
-4.48%
TELIF - ACUT
11%
Poorly correlated
+9.81%
BLTE - ACUT
11%
Poorly correlated
-0.93%
More

BLTE and

Correlation & Price change

A.I.dvisor indicates that over the last year, BLTE has been loosely correlated with RAIN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BLTE jumps, then RAIN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLTE
1D Price
Change %
BLTE100%
-0.93%
RAIN - BLTE
48%
Loosely correlated
+6.24%
ACOG - BLTE
24%
Poorly correlated
+0.99%
ALEC - BLTE
24%
Poorly correlated
-8.71%
CLDX - BLTE
22%
Poorly correlated
-0.76%
HRMY - BLTE
22%
Poorly correlated
-0.79%
More